SCHEMBL1340374

SCHEMBL1340374

CCOC(=O)c1nc(C)oc1-c1cccc(F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 2/20 0.53
ALDH1A1 P00352 3/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
TARBP2 Q15633 4/20 0.46
CSNK1D P48730 1/20 0.45
JAK2 O60674 1/20 0.45
JAK3 P52333 1/20 0.45
ELANE P08246 2/20 0.45
KDM4E B2RXH2 2/20 0.44
HPGD P15428 2/20 0.44
KMT2A Q03164 2/20 0.44
HSD17B10 Q99714 1/20 0.44
FPR2 P25090 1/20 0.44
CYP1A2 P05177 2/20 0.42
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4738316 0.87 TARBP2 (0.48) ALDH1A1TARBP2JAK2JAK3ELANE
SCHEMBL4786522 0.85 ALOX5 (0.55) TRPM8ALDH1A1TARBP2JAK2JAK3
SCHEMBL1965950 0.84 MEN1 (0.55) ALDH1A1LMNAHTTTARBP2KDM4E
SCHEMBL4738984 0.84 GABRA2 (0.51) TRPM8ALDH1A1LMNATARBP2KDM4E
SCHEMBL1968359 0.84 TARBP2 (0.59) TRPM8ALDH1A1LMNATARBP2KDM4E
SCHEMBL1969979 0.84 TARBP2 (0.50) ALDH1A1TARBP2CSNK1DELANEKDM4E
SCHEMBL1167044 0.83 PIN1 (0.50) TRPM8KDM4EFPR2SMN1; SMN2
SCHEMBL13256981 0.80 HTT (0.55) TRPM8ALDH1A1LMNAHTTTARBP2
SCHEMBL9586836 0.80 FBP1 (0.51) TRPM8ALDH1A1LMNAHTTCSNK1D
SCHEMBL20028178 0.80 TRPM8 (0.53) TRPM8ALDH1A1LMNAHTTTARBP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063099-B2 Trans-3-aza-bicyclo[3.1.0]hexane derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2011-11-22 US disclosed
EP-2185512-B1 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-12-29 EP disclosed
US-20100204285-A1 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-08-12 US disclosed
EP-2185512-A2 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-05-19 EP disclosed
WO-2009016560-A2 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-02-05 WO disclosed
WO-2008087611-A2 PYRROLIDINE- AND PIPERIDINE- BIS-AMIDE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204285-A1 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES HCRTR1, HCRTR2, CNR1 TRPM8 655/4885ALDH1A1 747/4885LMNA 2389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.